With a rich background that began in clinical practice and evolved into strategic leadership within the pharmaceutical industry, my career has been driven by a singular mission: to transform the lives of patients facing cardiovascular, rare, and genetic diseases. While my foundation is deeply rooted in Medical Affairs, my expertise extends across Real-World Evidence (RWE) and Clinical Development, enabling me to bring a unique perspective to every role I've undertaken—from Novartis and Portola to MyoKardia, BMS, Renovacor, and now Lexeo Therapeutics.I’ve been privileged to lead the launch of three groundbreaking therapies:~ENTRESTO® for Heart Failure~ANDEXXA® for Factor Xa Inhibitor Reversal~CAMZYOS® for Hypertrophic CardiomyopathyEach of these achievements is more than a milestone; they are steps toward a future where innovative therapies bring new hope to patients and their families. My commitment to this work is profoundly personal, shaped by the loss of my father to cancer—a loss that instilled in me a deep resolve to make a meaningful impact for patients who are often underserved and overlooked.I am passionate about unlocking new pharmaceutical frontiers and harnessing my experience across the product lifecycle to deliver solutions where they are needed most. I lead with a vision that inspires teams to think boldly, take calculated risks, and achieve outcomes that redefine what is possible in patient care. My approach is collaborative and empowering, fostering environments where innovation thrives, and every team member feels motivated to contribute to a shared goal.Every day, I am driven by the courage of clinical trial participants who trust us to find better answers. I aim to push the boundaries of what’s possible, creating a brighter future where every patient has a fighting chance, and every family has a reason to hope.